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Effects of Ankaferd hemostat on the synovial fluid of patients
with osteoarthritis
Mehmet Akif ÖZTÜRK1, Zeliha KOÇAK TUFAN2, Mehmet Derya DEMİRAĞ1,
İbrahim Celalettin HAZNEDAROĞLU3

Aim: Ankaferd Blood Stopper (ABS) is a novel topical hemostatic agent with antiinfective, wound healing, and
antineoplastic properties. In this study, we evaluated the macroscopic and biochemical effects of ABS in the joint fluid
of patients with osteoarthritis.
Materials and methods: Synovial fluid samples were obtained from 10 patients with osteoarthritis (5 women, 5 men;
mean age 57.6 ± 11.2 years). From each patient, 4 mL of synovial fluid was drawn and put into 2 different serum
separator tubes, and 1 mL of ABS was added to the first sample and 1 mL of 0.9% saline was added to the second sample.
Macroscopic evaluation and biochemical analyses for glucose, protein, albumin, and lactate dehydrogenase (LDH) were
performed.
Results: The addition of ABS into synovial fluid revealed a rapid and apparent reaction resulting in dense coagulation
within seconds in all of the samples. No reaction was observed in the saline group. Total protein, albumin, globulin, and
LDH levels significantly decreased in the ABS group, while glucose levels remained unchanged.
Conclusion: ABS can work in the synovial fluid, causes rapid frozen gel-like solidification, and decreases the protein
component of the synovial fluid. This observation, together with hemostatic and wound healing properties of ABS,
might provide an important starting point for testing its actions on distinct hemorrhagic, neoplastic, or inflammatory
joint disorders.
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Introduction
Ankaferd Blood Stopper (ABS) is a traditional drug
that has been used as a hemostatic agent for centuries
in Anatolia. It has recently been approved by the
Ministry of Health in Turkey as a topical hemostatic
agent for clinical hemorrhages (1-3). ABS is a
standardized mixture of the plants Thymus vulgaris
(dried leaf), Glycyrrhiza glabra (dried leaf), Vitis
vinifera (dried leaf), Alpinia officinarum (dried leaf),
and Urtica dioica (dried root), each of which has some
effects on the endothelium, blood cells, angiogenesis,
cellular proliferation, vascular dynamics, and/or cell

mediators (1). The basic mechanism of the hemostatic
action of ABS is the formation of a protein network
that provides focal attachment points for very rapid
vital erythrocyte aggregation like an “erythrocyte
magnet”. The ABS-induced protein network enriched
with blood cells, particularly erythrocytes, covers the
primary and secondary hemostatic system without
disturbing individual coagulation factors or platelets
(1-5). ABS was as effective as other hemostatic and
sealant agents (Glubran 2, FloSeal, and Celox) that
have already been licensed for use in controlling
kidney surgery bleeding with comparable warm
ischemia time and hemostasis time values (6).
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Apart from being an alternative hemostatic
medicine for intractable bleedings, ABS has
many other effects at the cellular level, including
antiinfective (7,8), wound healing (9,10), and
antineoplastic properties (11,12), and to restore
and maintain tissue homeostasis (1). Recently,
ABS also formed aggregates of protein network in
the pancreatic fluid and induced frozen gel-like
solidification (13). The effect of ABS on synovial fluid
has not yet been investigated although its effects on
pancreatic fluid (13) and blood plasma (1) disclosed
striking in vitro effects transferable to in vivo models.
The aim of this study was to assess the macroscopic
and biochemical effects of ABS in the joint fluid of
patients with osteoarthritis.

each patient. In the first step, macroscopic evaluation
of those saline and ABS groups were performed.
Subsequently the tubes were left for 30 min. The
tubes were then centrifuged for 15 min at 1000 × g.
Aliquots were obtained and stored at –80 °C until
assaying. Biochemical analyses for glucose, protein,
albumin, and lactate dehydrogenase (LDH) were
performed by commercially available biochemical
tests. The comparisons between the ABS and saline
groups were made using the Wilcoxon rank test. P ≤
0.05 was considered statistically significant.
Approval for this study was obtained from the
Local Ethics Committee.
Results

Materials and methods
Synovial fluid obtained from 5 women and 5 men
(age 57.6 ± 11.2 years) for the effusive complication
of knee osteoarthritis was utilized. Following the
arthrocentesis, 4 mL of synovial fluid from each
patient was put into 2 different serum separator tubes.
Then 1 mL of ABS was added to the first sample, and 1
mL of 0.9% saline was added to the second sample of

A

The addition of ABS into synovial fluid revealed
a rapid and apparent reaction resulting in dense
coagulation within seconds in all of the samples
(Figure 1A and 1B). No reaction was observed in the
saline group.
Biochemical analysis revealed a significant
decrease in the protein components of plasma in the
ABS group (Table). The decreases were observed in
all of the protein components, namely albumin and

B

Figure 1A. The macroscopic figure of the synovial fluid before the addition of ABS.
Figure 1B. The macroscopic figure of the synovial fluid after the addition of ABS.
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Table. Comparison of biochemical parameters in the ABS group and the control saline group (n = 10). All of the values are presented
as median (min-max).

After the addition of SF

After the addition of ABS

P

Glucose, mg/dL

61 (27-129)

63 (33-121)

0.47

Total protein (g/dL)

2.5 (1.5-5.2)

0.2 (0.1-1.8)

0.008

Albumin (g/dL)

1.5 (0.9-2.2)

0.1 (0-1.1)

0.011

Globulin (g/dL)

1.3 (0.6-3.1)

0.2 (0-0.9)

0.012

LDH (U/L)

78 (39-210)

2.0 (0-6)

0.012

ABS: Ankaferd blood stopper, LDH: lactate dehydrogenase.

globulin, as well as enzymatic component represented
by LDH (P < 0.05 for each parameter). However,
glucose levels remained unchanged (P > 0.05).
Discussion
We investigated macroscopic and biochemical
effects of ABS in the synovial fluid of patients with
osteoarthritis. We macroscopically observed rapid
frozen gel-like solidification, and the biochemical
analyses showed decreases in protein, albumin,
globulin, and LDH levels, while glucose levels
remained unchanged.
Previous studies demonstrated that the addition
of ABS to plasma and serum caused rapid formation
of an encapsulated protein network, which provided
focal points for erythrocyte aggregation. Furthermore,
they observed decreases in plasma fibrinogen,
protein, albumin, and globulin levels without any
changes in the clotting factors (factors II, V, VII, VIII,
IX, X, XI, and XIII). Therefore, rather than affecting
an individual clotting factor, ABS acts by forming
a protein mesh and affects the entire physiological
hemostatic process that controls bleeding (2-5).
ABS can also work in other tissue fluids such as
pancreatic fluid. Recently, ABS-induced frozen
gel-like solidification in the pancreatic fluid, and
cytopathological examination demonstrated a cluster
of aggregated proteinous material of the pancreatic
fluid. Biochemical analyses revealed decreases in
amylase, protein, and albumin levels (13).
Synovial fluid is an ultrafiltrate of plasma, with only
small amounts of higher molecular weight proteins
such as fibrinogen, complement, globulin, and other
immunoglobulins, and its glucose level is nearly
770

equal to that of blood. Synovia fluid is supplemented
with high-molecular weight, saccharide-rich
molecules, especially hyaluronans, produced by type
B synoviocytes. Normally, synovial fluid contains
few cells (<200/mm3), mainly chondrocytes and
synoviocytes, and the polymorphonuclear leukocyte
(PNL) percentage is low (<25%) (14,15). A small
quantity of joint fluid is present in the normal knee.
Normal fluid is difficult to aspirate, and it is an ethical
issue to aspirate joint fluid from asymptomatic
individuals. On the other hand, joint effusion is often
observed in osteoarthritis, which is regarded as a
joint disease with a low inflammatory component.
Synovial effusion in patients with osteoarthritis is
noninflammatory in nature, with transparent clarity,
normal glucose levels, 50-1000 cells <200/mm3, and
low PNL percentage (15). Hence, we preferred to use
the synovial fluid of osteoarthritis patients in order
to minimize the confounding effect of inflammatory
cells and mediators on the effects of ABS. All of the
synovial fluid samples in our study were transparent,
and protein, LDH, and glucose levels were compatible
with noninflammatory synovial effusion. After the
addition of ABS, the synovial fluid demonstrated
rapid frozen gel-like solidification, supporting the
hypothesis that ABS can work in other tissue fluids,
together with decrements in the levels of protein
components of the synovial fluid. Our observation
suggests that ABS could promote the aggregation
of both the protein components as well as highmolecular weight saccharide-rich hyaluronic acid in
synovial fluid.
ABS could help to control bleeding in defective
hemostasis. Two animal models supported this
hypothesis. In the first model, rats were treated either
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with warfarin (2 mg/kg) or a vehicle (0.9% NaCl),
orally before bilateral hind leg amputation. ABS was
administered topically to 1 of the amputated legs.
Topical ABS administration to the amputated leg
shortened the duration of bleeding markedly in both
the untreated and warfarin-treated rats. Furthermore,
the amount of bleeding in the ABS-administered
amputated leg showed an approximate 50% decrease
compared to the warfarin-treated group (16). In
the second model, the rats were pretreated with
acetylsalicylic acid or enoxaparin sodium or did not
receive any anticoagulant. ABS was administered
to the cut tails of the studied animals. Topical ABS
administration reduced both the duration and the
amount of bleeding in the acetylsalicylic acid-treated
and enoxaparin-treated animals (17). Those 2 in
vivo studies provide important data that ABS has a
therapeutic potential for the management of patients
with deficient hemostasis in clinical medicine. This
hypothesis was further supported by a number of
case reports, which demonstrated that topical ABS
application helped to control bleeding in patients
with disseminated intravascular coagulation,
hemophilia A, von Willebrand disease, hereditary
thrombocytopenia, and Glanzmann thrombasthenia
(18-23).
In addition to its hemostatic effect, ABS also has
wound healing properties. Topical ABS reduced
excisional bleeding in the experimental burn injury
model (10). In an animal model of bone defects
experimentally created in the right and left tibiae,
over 60% of the defects treated with ABS were free of

inflammation, the ABS-treated group showed lower
fibrosis rate than the untreated control group, and
the defects treated with ABS showed more intense
new bone formation and less occurrence of necrosis,
suggesting that ABS decreased the inflammation,
necrosis process, and increased the new bone
formation in early bone healing period (9).
Hemarthrosis is a frequent problem in patients
with hereditary hemorrhagic diatheses, especially
in hemophilia A, and can subsequently cause
progressive arthropathy due to fibrosis or ankylosis.
The management of this condition requires expensive
factor replacement, which is not always satisfactory
(24). Our results and previous experience with ABS,
demonstrating its hemostatic effects in patients with
defective hemostasis and wound healing properties,
suggest that ABS might offer an alternative therapeutic
approach for those patients. In vivo experiments with
animal models of hemarthrosis should be performed
to test this hypothesis.
Conclusion
In summary, we demonstrated for the first time
that ABS can work in the synovial fluid, causes
rapid frozen gel-like solidification, and decreases
the protein component of synovial fluid. This
observation, together with hemostatic and wound
healing properties of ABS, might provide an initial
step for developing an intraarticular agent for the
management of hemarthrosis, especially in patients
with defective hemostasis.
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